Seelos Therapeutics Analyst Ratings
Seelos Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/15/2023 | 53.85% | Cantor Fitzgerald | → $2 | Reiterates | Overweight → Overweight |
| 06/23/2023 | 53.85% | Cantor Fitzgerald | → $2 | Reiterates | Overweight → Overweight |
| 06/23/2023 | 207.69% | Benchmark | $4 → $4 | Reiterates | Speculative Buy → Speculative Buy |
| 05/16/2023 | 53.85% | Cantor Fitzgerald | $3 → $2 | Maintains | Overweight |
| 05/15/2023 | 207.69% | BTIG | $11 → $4 | Maintains | Buy |
| 03/30/2023 | 746.15% | BTIG | → $11 | Maintains | Buy |
| 03/24/2023 | 207.69% | Benchmark | $6 → $4 | Maintains | Buy |
| 02/13/2023 | 823.08% | BTIG | $12 → $12 | Maintains | Buy |
| 04/28/2022 | 823.08% | BTIG | → $12 | Maintains | Buy |
| 03/14/2022 | 207.69% | B. Riley Securities | $6 → $4 | Maintains | Buy |
| 03/08/2022 | 130.77% | Cantor Fitzgerald | $5 → $3 | Maintains | Overweight |
| 09/27/2021 | 515.38% | Roth Capital | $2.5 → $8 | Upgrades | Neutral → Buy |
| 08/10/2021 | 92.31% | Roth Capital | $4 → $2.5 | Maintains | Neutral |
| 07/01/2021 | 515.38% | Guggenheim | → $8 | Initiates Coverage On | → Buy |
| 06/01/2021 | 669.23% | Cantor Fitzgerald | → $10 | Initiates Coverage On | → Overweight |
| 03/30/2021 | 1053.85% | B. Riley Securities | → $15 | Initiates Coverage On | → Buy |
| 03/12/2021 | 976.92% | BTIG | → $14 | Initiates Coverage On | → Buy |
| 11/18/2019 | 53.85% | HC Wainwright & Co. | $4 → $2 | Maintains | Buy |
| 11/14/2019 | — | Benchmark | Initiates Coverage On | → Speculative Buy | |
| 05/14/2019 | — | Roth Capital | Initiates Coverage On | → Buy | |
| 05/10/2019 | 207.69% | HC Wainwright & Co. | → $4 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 08/15/2023 | 53.85% | 坎托·菲茨杰拉德 | → 2 美元 | 重申 | 超重 → 超重 |
| 06/23/2023 | 53.85% | 坎托·菲茨杰拉德 | → 2 美元 | 重申 | 超重 → 超重 |
| 06/23/2023 | 207.69% | 基准 | 4 美元 → 4 美元 | 重申 | 投机性买入 → 投机性买入 |
| 05/16/2023 | 53.85% | 坎托·菲茨杰拉德 | 3 美元 → 2 美元 | 维护 | 超重 |
| 05/15/2023 | 207.69% | BTIG | 11 美元 → 4 美元 | 维护 | 购买 |
| 03/30/2023 | 746.15% | BTIG | → 11 美元 | 维护 | 购买 |
| 2023 年 3 月 24 日 | 207.69% | 基准 | 6 美元 → 4 美元 | 维护 | 购买 |
| 02/13/2023 | 823.08% | BTIG | 12 美元 → 12 美元 | 维护 | 购买 |
| 04/28/2022 | 823.08% | BTIG | → 12 美元 | 维护 | 购买 |
| 03/14/2022 | 207.69% | B. 莱利证券 | 6 美元 → 4 美元 | 维护 | 购买 |
| 03/08/2022 | 130.77% | 坎托·菲茨杰拉德 | 5 美元 → 3 美元 | 维护 | 超重 |
| 09/27/2021 | 515.38% | 罗斯资本 | 2.5 美元 → 8 美元 | 升级 | 中性 → 买入 |
| 2021 年 10 月 8 日 | 92.31% | 罗斯资本 | 4 美元 → 2.5 美元 | 维护 | 中立 |
| 07/01/2021 | 515.38% | 古根海姆 | → 8 美元 | 启动覆盖开启 | → 购买 |
| 06/01/2021 | 669.23% | 坎托·菲茨杰拉德 | → 10 美元 | 启动覆盖开启 | → 超重 |
| 03/30/2021 | 1053.85% | B. 莱利证券 | → 15 美元 | 启动覆盖开启 | → 购买 |
| 2021 年 12 月 3 日 | 976.92% | BTIG | → 14 美元 | 启动覆盖开启 | → 购买 |
| 11/18/2019 | 53.85% | HC Wainwright & Co. | 4 美元 → 2 美元 | 维护 | 购买 |
| 2019 年 11 月 14 日 | — | 基准 | 启动覆盖开启 | → 投机性买入 | |
| 2019 年 5 月 14 日 | — | 罗斯资本 | 启动覆盖开启 | → 购买 | |
| 2019 年 10 月 5 日 | 207.69% | HC Wainwright & Co. | → 4 美元 | 启动覆盖开启 | → 购买 |
What is the target price for Seelos Therapeutics (SEEL)?
Seelos Therapeutics（SEEL）的目标价格是多少？
The latest price target for Seelos Therapeutics (NASDAQ: SEEL) was reported by Cantor Fitzgerald on August 15, 2023. The analyst firm set a price target for $2.00 expecting SEEL to rise to within 12 months (a possible 53.85% upside). 8 analyst firms have reported ratings in the last year.
坎托·菲茨杰拉德于2023年8月15日公布了Seelos Therapeutics（纳斯达克股票代码：SEEL）的最新目标股价。这家分析公司将目标股价定为2.00美元，预计SEEL将在12个月内升至12个月内（可能上涨53.85％）。去年有8家分析公司公布了评级。
What is the most recent analyst rating for Seelos Therapeutics (SEEL)?
分析师对Seelos Therapeutics（SEEL）的最新评级是多少？
The latest analyst rating for Seelos Therapeutics (NASDAQ: SEEL) was provided by Cantor Fitzgerald, and Seelos Therapeutics reiterated their overweight rating.
Seelos Therapeutics（纳斯达克股票代码：SEEL）的最新分析师评级由坎托·菲茨杰拉德提供，Seelos Therapeutics重申了他们的增持评级。
When is the next analyst rating going to be posted or updated for Seelos Therapeutics (SEEL)?
Seelos Therapeutics（SEEL）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Seelos Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Seelos Therapeutics was filed on August 15, 2023 so you should expect the next rating to be made available sometime around August 15, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Seelos Therapeutics的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月进行一次评级，因此每家公司每年应该获得4个评级。Seelos Therapeutics的最后一次评级是在2023年8月15日提交的，因此你应该预计下一个评级将在2024年8月15日左右公布。
Is the Analyst Rating Seelos Therapeutics (SEEL) correct?
分析师对 Seelos Therapeutics (SEEL) 的评级正确吗？
While ratings are subjective and will change, the latest Seelos Therapeutics (SEEL) rating was a reiterated with a price target of $0.00 to $2.00. The current price Seelos Therapeutics (SEEL) is trading at is $1.30, which is within the analyst's predicted range.
尽管评级是主观的，将会发生变化，但最新的Seelos Therapeutics（SEEL）评级得到了重申，目标股价为0.00美元至2.00美元。Seelos Therapeutics（SEEL）目前的交易价格为1.30美元，在分析师的预测区间内。
译文内容由第三方软件翻译。